Expanded week of dedicated sessions and trends on the world’s second largest pharma market
CPhI and P-MEC China 2017 will be held on June 20–22 in Shanghai New International Expo Center.
The event will be hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers and Exporters (CCCMHPIE), and co-organised by Shanghai UBM Sinoexpo.
Concurrent with the show, the first ever edition of “China Pharma Week” will be launched – 19-23 June 2017 – with 15 important meetings and events held in Shanghai and neighbouring regions.
The event covers six core themes, including Leadership, Business, Networking, Recognition, Knowledge and Innovation, providing industry professionals richer content and analysis.
Conferences and forums will gather global leaders of the pharmaceutical industry to engage in thought-provoking discussions on the latest trends in the pharma economy and technology.
The forums include:
Additionally, the organises will select a list of the Top 100 Internationalised Companies in 2016, to raise the international recognition and influence of the most prominent global Chinese pharmaceutical enterprises.
InnoPack, EP and Clean Tech, NEX Innovative Product Show and Discovery Tour will all showcase Chinese and overseas quality products and advanced technology.
CPhI China Pharma Week will offer an even more comprehensive knowledge and networking platform.
The five-day China Pharma Week will also include plant visits; the Women in Leadership Forum; and Night of Huangpu River Cruise Networking Dinner, which are collectively designed to build a more effective socialising platform for Chinese and global pharmaceutical enterprises.
CPhI and P-MEC China encompasses the entire supply chain from APIs, fine chemical and intermediates and excipients, dosage forms, preparations, natural extracts, biopharmaceuticals, contract research, pharmaceutical machinery, packaging materials, laboratory instruments and pharmaceutical logistics.
More than 2,800 exhibitors will greet over 40,000 professional visitors from more than 120 countries to sustain the business relationships that will drive tomorrow’s growth.
With an enormous ingredients sector and an expanding middle class, there are now many new opportunities for both domestic and international companies.
Rutger Oudejans, Brand Director Pharma at UBM EMEA, said: “Pharma R and D and production in China has grown rapidly in the last few years, both in terms of volume production and evolved its quality and regulatory environment.”
“CPhI China has grown to be the single most influential meeting point for pharma suppliers and customers.”
“This year we are introducing CPhI China Pharma Week to offer an even more comprehensive and bilingual knowledge and networking platform, covering all aspects of the world’s second largest pharma market.”
“With the Government investing heavily in R and D research, new regulations like MAH opening-up the market for contract services, an enormous ingredients sector, along with an expanding middle class, there are now many new opportunities for both domestic and international companies.”
“That’s why attending this week-long programme of content-led analysis and insights, coupled with specialist networking events, is absolutely essential for any executive looking to launch, expand or find partners in this vast pharma economy.”